These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 21747976)

  • 1. Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor.
    Essick EE; Sam F
    Int J Hypertens; 2011; 2011():346985. PubMed ID: 21747976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
    Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
    Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
    Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
    Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endothelin-aldosterone axis and cardiovascular diseases.
    Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P
    Praxis (Bern 1994); 1996 Feb; 85(8):227-33. PubMed ID: 8701189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?
    Emdin M; Fatini C; Mirizzi G; Poletti R; Borrelli C; Prontera C; Latini R; Passino C; Clerico A; Vergaro G
    Clin Chim Acta; 2015 Mar; 443():85-93. PubMed ID: 25445411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis.
    Böckmann I; Lischka J; Richter B; Deppe J; Rahn A; Fischer DC; Heineke J; Haffner D; Leifheit-Nestler M
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why are mineralocorticoid receptor antagonists cardioprotective?
    Chai W; Danser AH
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):153-62. PubMed ID: 17075718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
    Nakagawa H; Oberwinkler H; Nikolaev VO; Gaßner B; Umbenhauer S; Wagner H; Saito Y; Baba HA; Frantz S; Kuhn M
    Circ Heart Fail; 2014 Sep; 7(5):814-21. PubMed ID: 25027872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoids, salt, hypertension: effects on the heart.
    Young MJ; Funder JW
    Steroids; 1996 Apr; 61(4):233-5. PubMed ID: 8733007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone antagonists in hypertension and heart failure.
    Mantero F; Lucarelli G
    Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease.
    Gorini S; Marzolla V; Mammi C; Armani A; Caprio M
    Biomolecules; 2018 Sep; 8(3):. PubMed ID: 30231508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
    Sowers JR; Whaley-Connell A; Epstein M
    Ann Intern Med; 2009 Jun; 150(11):776-83. PubMed ID: 19487712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity.
    Feraco A; Armani A; Mammi C; Fabbri A; Rosano GM; Caprio M
    J Steroid Biochem Mol Biol; 2013 Sep; 137():99-106. PubMed ID: 23454117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction.
    Bender SB; DeMarco VG; Padilla J; Jenkins NT; Habibi J; Garro M; Pulakat L; Aroor AR; Jaffe IZ; Sowers JR
    Hypertension; 2015 May; 65(5):1082-8. PubMed ID: 25712719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.
    Whaley-Connell A; Habibi J; Rehmer N; Ardhanari S; Hayden MR; Pulakat L; Krueger C; Ferrario CM; DeMarco VG; Sowers JR
    Metabolism; 2013 Jun; 62(6):861-72. PubMed ID: 23352204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease.
    Funck RC; Wilke A; Rupp H; Brilla CG
    Adv Exp Med Biol; 1997; 432():35-44. PubMed ID: 9433509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
    Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
    Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.